Status and phase
Conditions
Treatments
About
Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subjects with advanced malignant solid tumors.
Full description
Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subjects with advanced malignant solid tumors. Secondary objectives are to determine preliminary Pharmacokinetics of PM02734, to explore the relationships between pharmacokinetics and pharmacodynamics. To evaluate the preliminary pharmacokinetics/pharmacodynamics correlation and to evaluate the preliminary antitumor activity of PM02734. The trial will be conducted in compliance with the protocol, GCP and applicable regulatory requirements.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Voluntary written informed consent of the subject obtained before any study-specific procedure.
Histologically or cytologically confirmed malignant solid tumor.
Subjects with malignancies for which no standard therapy would reasonably be expected to result in cure or palliation.
Age ≥ 18 years.
Subject with measurable or non-measurable disease using the RECIST criteria (only subjects with measurable disease are allowed to enter the expanded cohort).
Recovery from any drug-related adverse event derived from previous treatment, excluding alopecia and NCI-CTCAE grade 1 symptomatic peripheral neuropathy.
Laboratory values within 7 days prior to first infusion:
Performance status (ECOG) ≤ 2 .
Life expectancy ≥ 3 months.
Left ventricular ejection fraction (LVEF) within normal limits.
Women of childbearing potential must have a negative serum pregnancy test before study entry. Both men and women must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment. Acceptable methods of contraception include complete abstinence, IUD, oral contraceptive, subdermal implant and double barrier (condom with a contraceptive sponge or contraceptive suppository).
Exclusion criteria
Prior therapy with PM02734.
Pregnant or lactating women.
Less than 4 weeks from radiation therapy (8 weeks in case of extensive prior radiotherapy) or last dose of hormonal therapy, biological therapy or chemotherapy (6 weeks in case of nitrosourea, mitomycin C, or high-dose chemotherapy).
Evidence of progressive CNS metastases or any symptomatic brain or leptomeningeal metastases.
Evidence of extensive liver metastases ( more than 5 hepatic nodules and some of them greater than 5 cm in diameter)
Other relevant diseases or adverse clinical conditions:
Limitation of the subject's ability to comply with the treatment or to follow-up at a participating protocol. Subjects registered on this trial must be treated and followed at a participating center.
Treatment with ongoing anti-coagulation.
Treatment with any investigational product in the 30 days period prior to the first infusion.
Known hypersensitivity to any of the components of the drug product.
Primary purpose
Allocation
Interventional model
Masking
56 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal